Document is current
Any future updates will be listed below
-
Authors
Targum, Steven D. https://orcid.org/0000-0003-1054-5197
Schappi, Jeffrey
Koutsouris, Athanasia
Bhaumik, Runa
Rapaport, Mark H.
Rasgon, Natalie https://orcid.org/0000-0002-2894-2353
Rasenick, Mark M. https://orcid.org/0000-0003-2405-4364
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R43MH097370, R41MH113398)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Veterans Affairs (BX00149, BX004475)
- License Information
-
More Information
Article History
Received: 1 October 2021
Revised: 13 November 2021
Accepted: 23 November 2021
First Online: 5 January 2022
Competing interests
: Dr. Targum is an employee of Signant Health and has received vendor grants and/or consulting fees from Acadia Pharmaceuticals Inc., Alkermes Inc., BioXcel Therapeutics Inc., Denovo Biopharma, EMA Wellness LLC, Epiodyne, Frequency Therapeutics, Functional Neuromodulation, Intra Cellular Therapies, Johnson and Johnson PRD, Karuna Therapeutics, Merck Inc., Methylation Sciences Inc., Navitor Pharmaceuticals Inc., and Sunovion Inc. during the past 3 years. Drs Schappi, Bhaumik, Rapaport and Rasgon, and Ms. Koutsouris report no conflicts of interest. Dr. Rasenick is co-founder and chief scientific officer of Pax Neuroscience. In the past three years he has consulted for Otsuka, Inc and has received research support from Lundbeck SA. He is also supported by grants from the Veterans Administration and is a research career scientist of the VA.
